Maximizing benefits of the levodopa/carbidopa intestinal gel: Systematic considerations, challenging convention and individualizing approaches

Abstract The levodopa/carbidopa intestinal gel (LCIG) is an efficacious treatment for Parkinson disease. The initiation and management of the LCIG requires a streamlined approach that takes into account patient heterogeneity. In this article we outline an over arching approach to this while highlighting steps that could be potentially modified in each individual, with the ultimate goal of achieving ideal clinical outcomes.

• Publication year

  2018

• Venue

  Basal Ganglia

• Publication date

  2018-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.BAGA.2018.12.002
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Levodopa‐carbidopa intestinal gel: is the naso‐jejunal phase a redundant convention?

  2018cited by this paper
• Percutaneous Endoscopic Transgastric Jejunostomy (PEG‐J) Tube Placement for Levodopa‐Carbidopa Intrajejunal Gel Therapy in the Interventional Radiology Suite: A Long‐term Follow‐up

  2018cited by this paper
• Insertion of percutaneous endoscopic gastrostomy tubes with jejunal extensions using the “wedge” technique: a novel method to prevent retrograde tube migration into the stomach

  2017cited by this paper
• Which patients discontinue? Issues on Levodopa/carbidopa intestinal gel treatment: Italian multicentre survey of 905 patients with long-term follow-up.

  2017cited by this paper
• Peripheral neuropathy in 30 duodopa patients with vitamins B supplementation

  2017cited by this paper
• Effects of levodopa/carbidopa intestinal gel versus oral levodopa/carbidopa on B vitamin levels and neuropathy

  2017cited by this paper
• Peripheral neuropathy associated with levodopa–carbidopa intestinal infusion: a long‐term prospective assessment

  2016cited by this paper
• 24‐Hour infusion of levodopa/carbidopa intestinal gel for nocturnal akinesia in advanced Parkinson's disease

  2016cited by this paper
• 24 h Levodopa-carbidopa intestinal gel may reduce falls and "unresponsive" freezing of gait in Parkinson's disease.

  2015cited by this paper
• Initiating intrajejunal infusion of levodopa/carbidopa intestinal gel: An outpatient model

  2015cited by this paper
• Long-Term Safety and Maintenance of Efficacy of Levodopa-Carbidopa Intestinal Gel: An Open-Label Extension of the Double-Blind Pivotal Study in Advanced Parkinson's Disease Patients

  2015cited by this paper
• Initiation and dose optimization for levodopa-carbidopa intestinal gel: Insights from phase 3 clinical trials.

  2015cited by this paper
• Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson's disease: Consensus from an international survey and discussion program.

  2015cited by this paper
• Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson's disease patients; 12-month interim outcomes.

  2015cited by this paper
• Best practice in placement of percutaneous endoscopic gastrostomy with jejunal extension tube for continuous infusion of levodopa carbidopa intestinal gel in the treatment of selected patients with Parkinson’s disease in the Nordic region

  2015cited by this paper
• Dopamine agonist withdrawal syndrome (DAWS) symptoms in Parkinson's disease patients treated with levodopa-carbidopa intestinal gel infusion.

  2015cited by this paper
• Guillain-Barre/CIDP-like neuropathy in two parkinsonian patients following intestinal levodopa/carbidopa treatment.

  2014cited by this paper
• Emerging issues on selection criteria of levodopa carbidopa infusion therapy: considerations on outcome of 28 consecutive patients

  2014cited by this paper
• Perceptions of symptoms and expectations of advanced therapy for Parkinson’s disease: preliminary report of a Patient-Reported Outcome tool for Advanced Parkinson’s disease (PRO-APD)

  2014cited by this paper
• Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study.

  2014cited by this paper
• How to organize multispecialty care for patients with Parkinson's disease.

  2014cited by this paper
• Direct endoscopic jejunosotomy for the administration of levodopa-carbidopa intestinal gel in Parkinson's disease.

  2014cited by this paper
• Sleep improvement with levodopa/carbidopa intestinal gel infusion in Parkinson disease

  2013cited by this paper
• Sa1549 The Fishing Line Method: a Simplified, Non-Traumatic Technique Facilitating Percutaneous Endoscopic Jejunostomy

  2013cited by this paper
• Sa1548 Self-Propelled Percutaneous Endoscopic Gastrojejunostomy (PEG-J): a Pilot Study

  2013cited by this paper
• Levodopa-carbidopa intestinal gel in advanced Parkinson's disease open-label study: interim results.

  2013cited by this paper
• Levodopa/carbidopa intestinal gel infusion long‐term therapy in advanced Parkinson’s disease

  2012cited by this paper
• Practical Guidance on How to Handle Levodopa/Carbidopa Intestinal Gel Therapy of Advanced PD in a Movement Disorder Clinic

  2012cited by this paper
• Oral and Infusion Levodopa-Based Strategies for Managing Motor Complications in Patients with Parkinson’s Disease

  2010cited by this paper
• Subacute axonal neuropathy in Parkinson's disease with cobalamin and vitamin B6 deficiency under duodopa therapy

  2010cited by this paper
• Enteral nutrition access devices.

  2010cited by this paper
• CSF Aβ42 and tau in Parkinson's disease with cognitive impairment

  2010cited by this paper
• Levodopa in the treatment of Parkinson’s disease

  2009cited by this paper
• Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's disease

  2009cited by this paper
• Intrajejunal levodopa infusion in Parkinson's disease: A pilot multicenter study of effects on nonmotor symptoms and quality of life

  2009cited by this paper
• Reversible encephalopathy and axonal neuropathy in Parkinson's disease during duodopa therapy

  2009cited by this paper
• Local infection after placement of percutaneous endoscopic gastrostomy tubes: a prospective study evaluating risk factors.

  2008cited by this paper
• The rationale for continuous dopaminergic stimulation in advanced Parkinson's disease.

  2007cited by this paper
• Long-term 24-hour duodenal infusion of levodopa: outcome and dose requirements.

  2006cited by this paper
• Phosphorylated tau predicts rate of cognitive decline in MCI subjects: A comparative CSF study

  2005cited by this paper

• Therapeutic Strategies to Treat or Prevent Off Episodes in Adults with Parkinson’s Disease

  2020cites this paper
• Pharmacotherapeutic Strategies to Treat or Prevent OFF Episodes in Adults with Parkinson's disease

  2020cites this paper